Skip to main content

Advertisement

Fig. 4 | Thrombosis Journal

Fig. 4

From: The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor

Fig. 4

Differences in clotting time in whole blood (thromboelastometry) after adding haemostatic agents in different concentrations. Differences in clotting time expressed as per cent reduction from baseline (rivaroxaban with no haemostatic agent added). The doses of the haemostatic agents are 80%, 100% and 125% of the suggested doses, as described under study design. Control level, the difference between the mean control value and the patient baseline values, is illustrated by the dotted line. a. Rivaroxaban-treated patients, the whole group, n = 50. b. Subgroup with the highest rivaroxabanconcentrations (>300 ng/L), n = 6. *p < 0.005. PCC: prothrombin complex concentrate, aPCC: activated prothrombin complex concentrate, rFVIIa: recombinant Factor VIIa

Back to article page